Seelos Therapeutics to Participate in The Benchmark Company Healthcare Conference

Seelos Therapeutics (Nasdaq: SEEL) announced its participation in The Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference on May 26, 2021.

Rhea-AI Summary

Seelos Therapeutics (Nasdaq: SEEL) announced its participation in The Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference on May 26, 2021. Raj Mehra, Ph.D., Chairman and CEO, will host individual meetings via conference calls. The company focuses on therapies for CNS disorders and rare diseases, with a portfolio targeting conditions like Major Depressive Disorder, PTSD, and ALS. More details about the conference can be found here.

Argus Session date unavailable

-1.21% session move Open Argus

Details

News Market Reaction – SEEL

The recorded move for SEEL in the trading session of this news was -1.21%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, May 21, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in The Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference on Wednesday, May 26, 2021.

Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 meetings via conference calls.

Additional information about the conference may be accessed here.  

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
https://seelostherapeutics.com/ 
https://twitter.com/seelostx 
https://www.linkedin.com/company/seelos

View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-benchmark-company-healthcare-conference-301296611.html

SOURCE Seelos Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Seelos Therapeutics participating in on May 26, 2021?

Seelos Therapeutics is participating in The Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference.

Who is hosting the 1x1 meetings for Seelos Therapeutics?

Raj Mehra, Ph.D., Chairman and CEO of Seelos Therapeutics, will host the 1x1 meetings.

What is the focus of Seelos Therapeutics?

Seelos Therapeutics focuses on developing therapies for central nervous system disorders and rare diseases.

What conditions does Seelos Therapeutics target?

Seelos Therapeutics targets conditions such as Acute Suicidal Ideation, Major Depressive Disorder, PTSD, ALS, and Sanfilippo syndrome.

Where can I find more information about Seelos Therapeutics?

More information about Seelos Therapeutics can be found on their official website: http://seelostherapeutics.com.